The Amgen TVEC team will be taking over responsibility for this product once the new re org is set. Onyx will be the hemonc therapeutic arm while Amgen will take over solid tumors. TH global TVec lead does not want to move to the Bay Area so he will bring those products to her. This is what is meant by onyx being displaced. Kryprolis and Blin team will initially be separate at onyx but will merge later. Solid onc moves back to TO.
Yeah because launching drugs under a CIA makes sense...all therapeutic Onc is moving north. TH didn't want to demoralize both the Blin team and the T-Vec team in the same week. Btw what does 'move back' mean. You have one dog CRC drug that you failed miserably at for almost a decade.
Nexavar does close to $1b in world wide sales. Bayer has not written it off. It is their biggest revenue generator in on oncology. The plans remains the same therapeutic Onc moves north supportive care stays in TO.
